Free Trial
CVE:MPH

Medicure (MPH) Stock Price, News & Analysis

Medicure logo
C$1.25 -0.02 (-1.57%)
As of 06/27/2025 02:56 PM Eastern

About Medicure Stock (CVE:MPH)

Key Stats

Today's Range
C$1.25
C$1.25
50-Day Range
C$0.83
C$1.27
52-Week Range
C$0.63
C$1.27
Volume
1,500 shs
Average Volume
4,035 shs
Market Capitalization
C$13.05 million
P/E Ratio
N/A
Dividend Yield
2.24%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

Receive MPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicure and its competitors with MarketBeat's FREE daily newsletter.

MPH Stock News Headlines

This Crypto Is Set to Explode in January
Free summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this means and how everyday investors like you can position themselves to potentially profit. The timing couldn't be more critical
Medicure Inc. (NGQ1.F)
Medicure Inc. (MPH.V)
MPH:CA Medicure Inc.
See More Headlines

MPH Stock Analysis - Frequently Asked Questions

Medicure's stock was trading at C$0.88 on January 1st, 2025. Since then, MPH shares have increased by 42.0% and is now trading at C$1.25.
View the best growth stocks for 2025 here
.

Medicure Inc. (CVE:MPH) announced its quarterly earnings data on Wednesday, May, 24th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of $0.04 by $0.37. The business earned $8.71 million during the quarter, compared to analyst estimates of $14.50 million. Medicure had a negative trailing twelve-month return on equity of 10.18% and a negative net margin of 9.65%.

Shares of MPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicure investors own include Dollarama (DOL), Alimentation Couche-Tard (ATD.B), Canoe EIT Income Fund (ENDTF), Allena Pharmaceuticals (ALNA), Hudbay Minerals (HBM), ProMetic Life Sciences (PLI) and Athersys (ATHX).

Company Calendar

Last Earnings
5/24/2017
Today
7/01/2025

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
CVE:MPH
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
19.15
P/E Growth
N/A
Net Income
-C$2.03 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$21.08 million
Cash Flow
C$0.50 per share
Price / Cash Flow
2.49
Book Value
C$1.91 per share
Price / Book
0.65

Miscellaneous

Free Float
N/A
Market Cap
C$13.05 million
Optionable
Not Optionable
Beta
0.90
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (CVE:MPH) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners